openPR Logo
Press release

Herceptin Biosimilars Market Detailed Analysis of Current Scenario with Growth Forecasts to 2028

04-26-2023 11:18 AM CET | Health & Medicine

Press release from: The Insight Partners

Herceptin Biosimilars Market

Herceptin Biosimilars Market

Herceptin is a monoclonal antibody, a cancer medication used in the treatment of breast cancer. Herceptin is called a "biologic" drug. It is made from a living organism and is also termed as a targeted therapy drug. Biologic drugs are very complex to make and very sensitive to change. A biosimilar is the biologic drug generic version. Herceptin is used as part of chemotherapy regimen for adjuvant treatment of lymph-node positive, protein-positive breast cancer and mainly administered intravenously in cancer patients; the dose of herceptin given to patients is evaluated based on patients' disease history and other physiological factors such as type of cancer or disease condition, height, and weight.

Get PDF Sample Copy of this Report -

Herceptin Biosimilars Market: Regional Analysis-

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2022 to 2028. These analyses will help the reader to understand the potential worth of investment in a particular region. The report offers in-depth assessment of the growth and other aspects of the Herceptin Biosimilars Market in important regions. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

Herceptin Biosimilars Market: Competitive Landscape-

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

Speak to Our Analyst at -

Company Profiles-

> Amgen Inc.
> AryoGen Biopharma
> Roche Holding AG
> Samsung bioepis Co,.Ltd.
> Biocon Limited
> Celltrion Inc.
> Pfizer Inc.
> Merck & Co., Inc.
> Gedeon Richter Plc
> Genor Biopharma Company Ltd

Leading market players and manufacturers are studied to help give a brief idea about them in the report. The challenges faced by them and the reasons they are on that position are explained to help make a well informed decision. Competitive landscape of Herceptin Biosimilars Market is given presenting detailed insights into the company profiles, developments, merges, acquisitions, economic status and best SWOT analysis.

NOTE: Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 analysis of markets and industries. Cordially get in touch for more details.

The herceptin biosimilars market is segmented on the basis of type, and application. On the basis of type, the market is segmented as breast cancer, gastric cancer, and others. On the basis of application, the market is segmented into hospitals and clinics, oncology centers, and others.

Order a copy of this research study at -

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
Phone: +1-646-491-9876

About The Insight Partners:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Herceptin Biosimilars Market Detailed Analysis of Current Scenario with Growth Forecasts to 2028 here

News-ID: 3030466 • Views:

More Releases from The Insight Partners

Orthopedic 3D Scanners Market Is Gaining Huge Growth In Upcoming Years
Orthopedic 3D Scanners Market Is Gaining Huge Growth In Upcoming Years
3D orthopaedic scanning devices are sophisticated technology-driven systems used to scan human body components for the detection and treatment of the defect. By means of its scanning capabilities, 3D orthopaedic scanning systems help to design uniquely customised products and to find further use in surgical procedures. Get More Details with Sample PDF Copy @ Orthopedic 3D Scanners Market: Competitive Landscape and Key Developments: • Delcam Plc • Allied OSI Labs • SCANNY3D S.r.l. • AGE Solutions S.r.l. • Orthopaedic Innovation Centre • Diasu
Prostate Cancer Diagnostics: A Guide to Understanding the Process
Prostate Cancer Diagnostics: A Guide to Understanding the Process
Prostate cancer diagnostics refers to the various tests and procedures used to diagnose prostate cancer in men. Early detection of prostate cancer is important for successful treatment and recovery. Several different diagnostic tests are available, including digital rectal exams, prostate-specific antigen (PSA) tests, and biopsies. With the increasing prevalence of prostate cancer. Get More Details with Sample PDF Copy @ Prostate Cancer Diagnostics Market: Competitive Landscape and Key Developments: • MDxHealth • Telo Genomics Corp
Aerospace Plastics Market Research Insights with Upcoming Trends Segmentation, Opportunities and Forecast to 2031
Aerospace Plastics Market Research Insights with Upcoming Trends Segmentation, O …
The Aerospace Plastics Market report by "The Insight Partners" entails detailed information regarding the dynamics affecting market valuation over the analysis period. It also covers the competitive landscape, market scope, and market segmentation. Get Sample Copy of Report at: Companies Profiled in this report includes: • SABIC • Victrex • Drake Plastics Ltd • Solvay • BASF SE • Evonik Industries AG • Vantage Plane Plastics • Paco Plastics & Engineering Inc. • 3P • Performance Plastics Products • Big Bear Plastics The report scrutinizes different business approaches and frameworks that
Consumer Genomics: A Guide to Understanding the Process
Consumer Genomics: A Guide to Understanding the Process
Consumer genomics market is growing as it is very frictionless. A patient can purchase a genetic test online and then receive a test kit by mail and collect a DNA sample in their own home. Patients will receive the results at home and don't need any guidance of a genetic counselor or medical practitioner. Get More Details with Sample PDF Copy @ Consumer Genomics Market: Competitive Landscape and Key Developments: •

All 5 Releases

More Releases for Herceptin

Herceptin Biosimilar Market | Industry Trends and Forecast 2022-2030
Acumen Research and Consulting has announced the addition of the "Herceptin Biosimilar Market" report to their offering. The Herceptin Biosimilar Market Report 2030 is an in depth study analyzing the current state of the Herceptin Biosimilar Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Herceptin Biosimilar Market provides analysis of global market covering the industry trends, recent
Herceptin Biosimilar Market 2021 Growth, COVID Impact, Trends Analysis Report 20 …
Herceptin is an anticancer drug used to treat breast cancer. It is a monoclonal antibody and is used with chemotherapy drugs. Also called targeted therapy. Trastuzumab is one of the brand name Herceptins, given by slow injection into a vein. Herceptin Biosimilar Market is thoroughly, accurate and comprehensively assessed in a report focusing on market dynamics, market competition, regional growth, segment analysis, and key growth strategies. Report buyers will have access
Herceptin Biosimilar Market to Exhibit Skyrocketing Expansion During 2020-2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry
Herceptin Biosimilar Market to Discern Steadfast Expansion During 2029
Global Herceptin Biosimilar Market: Overview Growing number of people living with gastric cancers and metastatic (spread) breast cancer is expected to drive demand opportunities for enterprises working in the global herceptin biosimilar market. Herceptin refers to a monoclonal antibody mainly utilized in the treatment of critical cancers like gastric cancers and metastatic (spread) breast cancer. An upcoming research report on the global herceptin biosimilar market provides a complete analysis of this market.
United States Herceptin Biosimilar Market 2017
In this report, the United States Herceptin Biosimilar Market 2017 is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: The West Southwest The Middle Atlantic New England The South The Midwest with sales (volume), revenue (value), market share and growth rate of Herceptin Biosimilar in
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or